|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Hypoxia-inducible factor 1α (HIF-1α) plays an important role in tumor growth and metastasis.
|
26115041 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
HIF-1, which is activated in human hilar cholangiocarcinomas, contributes to tumor cell survival following PDT in vitro.
|
26657503 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
HIF-1α regulates the interaction of chronic lymphocytic leukemia cells with the tumor microenvironment.
|
26825709 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
HIF-1α and VEGF expression was significantly related to tumor stage and lymph nodes and lung metastases (P < 0.05).
|
27173353 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
HIF-1 (hypoxia-inducible factor-1) regulates the expression of more than 70 genes involved in angiogenesis, tumor growth, metastasis, chemoresistance, and radioresistance.
|
27263528 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Hypoxia-inducible factor-1 α (HIF-1α) is a transcription factor that is dominantly expressed under hypoxia in solid tumor cells and is a key factor that regulates tumor.
|
28165392 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
HIF-1α overexpression was significantly associated with larger tumor size (OR = 2.28, 95% CI = 1.49-3.50, P = 0.017), advanced TNM stage (OR = 2.29, 95% CI = 1.50-3.49, P = 0.158), and lymph node metastasis (OR = 2.05, 95% CI = 1.19-3.53, P < 0.001), but not with poor differentiation (OR = 1.21, 95% CI = 0.55-2.64, P = 0.024).
|
28521842 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Hypoxia-inducible factor-1α (HIF-1α) is a transcription factor that is dominantly expressed under hypoxia in solid tumor cells and is a key factor of tumor regulation.
|
28684144 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
HIF-1α- Targeting Acriflavine Provides Long Term Survival and Radiological Tumor Response in Brain Cancer Therapy.
|
29097800 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
HIF-1α plays distinct roles in M1 and M2 macrophage polarization, which, in turn, regulates tumor cell immune escape and growth.
|
29330807 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Hypoxia-inducible factor‑1α (HIF‑1α) is known to play crucial roles in tumor radioresistance; however, the molecular mechanisms responsible for the promotion of tumor radioresistance by HIF‑1α remain unclear.
|
29658569 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
HIF-1α and c-Jun are key components of HIF-1 and AP-1, respectively, and are regulated by epidermal growth factor receptor (EGFR)-mediated cell signaling and tumor microenvironmental cues.
|
29858032 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Hypoxia-inducible factor-1α (HIF-1α) plays an important role in tumor growth, invasion, and metastasis.
|
30174456 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
HIF‑1α overexpression was closely associated with lymph node metastasis and tumor‑lymph node‑metastasis (TNM) stages.
|
30272364 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
HIF-1α positive expression was significantly associated with vascular invasion (P = 0.002), TNM stage (P = 0.005), HBV infection (P = 0.005), tumor size (P = 0.025) and portal vein tumor thrombus (P = 0.001) in HCC with liver cirrhosis.
|
30274686 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Hypoxia‑inducible factor‑1α (HIF‑1α) is upregulated in various tumors and associated with lymphangiogenesis and angiogenesis during tumor development and metastasis.
|
30431105 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
HIF-1α expression was significantly associated with tumor grade, depth of myometrial invasion, and lymph node metastasis (P = 0.014, 0.012, and 0.046, respectively).
|
30539847 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
HIF-1 and total HIF pathway activation scores were decreased with higher ascorbate in pRCC tumors (Spearman <i>r</i> = -0.38, <i>p</i> < 0.05 and <i>r</i> = -0.35, <i>p</i> < 0.05).This was not evident for ccRCC tumors.
|
30555801 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Hypoxia inducible factor-1α (HIF-1α) is a key regulator of cellular response to hypoxia and plays an important role in tumor growth, and HIF-1α gene single-nucleotide polymorphisms (SNPs) adversely affect the outcome in some cancers.
|
30678691 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Hypoxia-inducible factor-1α (HIF-1α) mediates tumor cell adaptation to hypoxic conditions and is a potentially important anticancer therapeutic target.
|
30755586 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Hypoxia inducible factor-1 α (HIF-1α) is the key responser adapted to tumor hypoxia.
|
30782242 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
HIF-1 pathway is one of the survival pathways activated in tumor in response to hypoxia.
|
30819620 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
HIF-1 pathway proteins were upregulated in tumor tissue and increased HIF-1 activation was associated with higher tumor grade and stage, with increased vascular invasion and necrosis, and with decreased disease-free and disease-specific survival.
|
30943919 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A negative role for TAp73, the full-length form that is often associated with tumor suppression, in blood vessel formation, is consistent with its general attributes and was proposed to be effected indirectly through the degradation of hypoxia-inducible factor 1α (HIF1-α), the master angiogenic regulator.
|
26711266 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
A series of assays were performed to detect the effects of curcumin on: i) Tumor weight and size; ii) Notch and hypoxia inducible factor 1 (HIF-1) mRNA expression by quantitative polymerase chain reaction; and iii) vascular endothelial growth factor (VEGF) and nuclear factor-κB (NF-κB) by immunohistochemistry.
|
30405819 |
2018 |